MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
This is a multinational, multicenter, double-blind, placebo-controlled study in approximately 1200 participants, who will be randomized to receive a single infusion of either NTLA-2001 or placebo.
Inclusion Criteria:
Exclusion Criteria:
medicalinformation@intelliatx.com1-857-285-6200 ext. 6
San Diego, California 92103, United States
Washington D.C., District of Columbia 20010, United States
New York, New York 10016, United States
Richmond, Virginia 23298, United States
Ciudad Autonoma de Buenos Aire, Argentina
Ciudad Autonoma de Buenos Aire, Argentina
Ribeirão Preto, Brazil
Bologna, Italy
Trieste, Italy